Literature DB >> 17973260

Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study.

Helena M Verkooijen1, Gerald Fioretta, Elisabetta Rapiti, Georges Vlastos, Isabelle Neyroud-Caspar, Pierre O Chappuis, Christine Bouchardy.   

Abstract

We evaluated the impact of a family history of breast/ovarian cancer on the risk of secondary leukemia following breast cancer. At the Geneva cancer registry, we identified 4,397 patients diagnosed with invasive breast cancer between 1990 and 2004. Patients were followed up for leukemia until the end of 2005. Family history was categorized as positive in patients with >or=1 first- or second-degree relative with breast/ovarian cancer. We compared leukemia rates in patients with positive and negative family histories with those expected in the general population, generating standardized incidence ratios (SIRs). With Cox regression analysis, we calculated adjusted risks of secondary leukemia in patients with familial risks compared to those without it. Breast cancer patients had a significantly increased risk of secondary acute leukemia (SIR 3.2, 95% CI: 1.2-6.9) but not of chronic leukemia (SIR 1.6, 95% CI: 0.6-3.5). Among patients with a positive family history (n = 1.125, 25.6%), the SIRs were 5.7 (95% CI: 1.2-16.6) for acute and 5.2 (95% CI: 1.4-13.3) for chronic leukemia. Among breast cancer patients, family history was independently associated with leukemia [adjusted hazard ratio (HR(adj)) of 3.2, 95% CI: 1.1-9.2, among patient with vs. without family history]. The effect of family history was stronger for chronic leukemia (HR(adj): 11.6, 95% CI 1.3-104.7) than for acute leukemia (HR(adj) 1.6, 95% CI: 0.4-6.6). Breast cancer patients with a family history of breast/ovarian have an increased risk of secondary leukemia, both compared to the general population as well as to breast cancer patients without family histories. This excess risk is largely due to the increased risk of secondary chronic leukemia. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 17973260     DOI: 10.1002/ijc.23212

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.

Authors:  Judith E Karp; Antonio C Wolff
Journal:  Cancer       Date:  2015-12-07       Impact factor: 6.860

2.  Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies.

Authors:  Jieqiong Liu; Zheyu Hu; Yuhua Feng; Shan Zeng; Meizuo Zhong
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.